OBJECTIVES:: Multiple Myeloma (MM) is a bone marrow-based plasma cell neoplasm; data regarding current treatment patterns in Brazil are scarce. Brazilian Public Healthcare System (SUS) defines two procedures for first (1L) and second-line (2L) treatment for MM and reimburses it through High Complexity Procedures Authorization (APAC) System. The objective of this analysis was to analyze 1L and 2L treatment patterns in MM reimbursed during 2012-2016 by SUS and compare them to current Brazilian treatment guideline (PCDT). METHODS::  All APACs for procedures 03.04.03.018-0 (1L) and 03.04.03.019-8 (2L) during 2012-2016 considering the International Classification of Disease Code (ICD-10) C90.0 were extracted from the ambulatory care information system (SIA/SUS) from the Brazilian Health Information System. A key for decoding all chemotherapy inputs was developed by two health professionals and validated by one oncologist and fuzzy matching method was applied. Patient characteristics and treatments were assessed using summary statistics. RESULTS:: Overall, 118,177 (1L) and 58,044 (2L) APACs were obtained, corresponding to 11,594 (1L) and 5,569 (2L) patients. Mean number of APACs per patient were 10.43±8.99 (1L) and 10.19±8.93 (2L). After Jan-2012, 8,947 patients in 1L and 3,486 in 2L were diagnosed with MM. Median time from first to last APAC was 7 months for 1L (IQR:2-13) and 6 months for 2L (IQR:2-13). Among patients in 1L, 48.6% were men; overall median age was 64 years (IQR:57-72). Drugs from 90.1% (1L) and 87.5% (2L) APACs could be decoded. Most used drug combinations reported for 1L-treatment were cyclophosphamide monotherapy (8.6%), cyclophosphamide+dexamethasone+thalidomide (7.7%) and melphalane+prednisone (4.9%); for 2L-treatment, cyclophosphamide monotherapy (9.7%), bortezomibe (6.3%) cyclophosphamide+dexamethasone+thalidomide (5.2%) were the most frequent. CONCLUSIONS::  The most reported drug was a monotherapy not included in the PCDT recommendations, all other frequent combinations were coherent with the current PCDT. The results found are limited by the uncertainty in data input in the database.